Asset Details
Do you wish to reserve the book?
Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease
Do you wish to request the book?
Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease
2024
Overview
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. Current treatments for DKD do not halt renal injury progression, highlighting an urgent need for therapies targeting key disease mechanisms. Our previous studies demonstrated that activating the Sigma-1 receptor (S1R) with fluvoxamine (FLU) protects against acute kidney injury by inhibiting inflammation and ameliorating the effect of hypoxia. Based on these, we hypothesized that FLU might exert a similar protective effect in DKD. Diabetes was induced in male Wistar rats using streptozotocin, followed by a seven-week FLU treatment. Metabolic and renal parameters were assessed along with a histological analysis of glomerular damage and fibrosis. The effects of FLU on inflammation, hypoxia, and fibrosis were tested in human proximal tubular cells and normal rat kidney fibroblasts. FLU improved renal function and reduced glomerular damage and tubulointerstitial fibrosis. It also mitigated inflammation by reducing TLR4, IL6, and NFKB1 expressions and moderated the cellular response to tubular hypoxia. Additionally, FLU suppressed TGF-β1-induced fibrotic processes and fibroblast transformation. These findings suggest that S1R activation can slow DKD progression and protect renal function by modulating critical inflammatory, hypoxic, and fibrotic pathways; therefore, it might serve as a promising novel drug target for preventing DKD.
Publisher
MDPI AG
Subject
/ Animals
/ Diabetes
/ Diabetes Mellitus, Experimental - metabolism
/ Diabetic Nephropathies - drug therapy
/ Diabetic Nephropathies - metabolism
/ Diabetic Nephropathies - pathology
/ Fibrosis
/ Fluvoxamine - therapeutic use
/ Glucose
/ Humans
/ Hypoxia
/ Ischemia
/ Kidney Tubules, Proximal - drug effects
/ Kidney Tubules, Proximal - metabolism
/ Kidney Tubules, Proximal - pathology
/ Male
/ Proteins
/ Rats
/ Receptors, sigma - metabolism
